Igor Vkv / Shutterstock.com
Natalia Gulyaeva and Maria Sedykh of Hogan Lovells look at the main drivers of collaboration in the pharmaceutical sector and the legal issues to keep in mind when handling partnerships in Russia.
The life sciences industry has remained dynamic even in the years of economic downturn. Clearly, this high IQ industry is smart enough to adjust to the changing market conditions and to see the silver lining.
Russia has been called a “pharmerging” country along with China, India, Mexico, and other developing markets with large populations.
These countries were once considered the saviours of big pharma companies, given the immense patent cliff in the US and Europe. But over the last few years, the sales growth in such “pharmerging” markets has decreased.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Natalia Gulyaeva, Maria Sedykh, Hogan Lovells, life sciences, pharmaceutical industry, research and development, R&D, CIS, PTO, patent,